Description
Specifications
- Form: White lyophilized powder
- Standard vial size: 5mg / 10mg
- Purity: ≥99% (HPLC & Mass Spec verified)
- Class: Triple agonist (GLP-1 / GIP / Glucagon receptors)
- Storage: Store lyophilized powder at -20°C; refrigerate at 2–8°C once reconstituted, use within 30 days
Overview
Retatrutide is a novel triple-agonist peptide, engineered to simultaneously activate the GLP-1, GIP, and glucagon receptors in a single molecule. It represents the newest generation of incretin-pathway research compounds and has generated significant interest in metabolic research circles for its multi-receptor mechanism.
Mechanism & Research Findings
By combining GLP-1 receptor agonism (satiety, insulin secretion), GIP receptor agonism (insulin sensitization), and glucagon receptor agonism (increased energy expenditure and hepatic lipid oxidation) in one compound, Retatrutide is studied as a model for understanding additive and synergistic effects across incretin and glucagon signaling pathways. Published Phase 2 clinical trial data has reported substantial reductions in body weight in trial participants, making it a heavily referenced compound in current obesity-pharmacology literature and receptor-polypharmacology research.
Research Applications
- Multi-receptor incretin pathway pharmacology
- Energy expenditure and hepatic lipid metabolism studies
- Comparative research against single- and dual-agonist GLP-1 compounds
For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.









Reviews
There are no reviews yet.